Comparative Pharmacology
Head-to-head clinical analysis: DEXACEN 4 versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACEN 4 versus STATROL.
DEXACEN-4 vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
10 mg orally once daily
None Documented
None Documented
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid